Table 1. Clinicopathologic and molecular characteristics of colorectal cancers from patients in the discovery set (N=1370).
| CIMP-N (N=1287, 93.9%) | CIMP-P1 (N=62, 4.6%) | CIMP-P2 (N=21, 1.5%) | P Overall | CIMP-N vs CIMP-P1 | CIMP-N vs CIMP-P2 | CIMP-P1 vs CIMP-P2 | |
|---|---|---|---|---|---|---|---|
| Age, median (min–max) | 62 (20–93) | 62 (39–80) | 71 (41–83) | 0.001 | > 0.999 | <0.001 | 0.002 |
| Sex | 0.046 | 0.110 | 0.800 | 0.870 | |||
| Female | 510 (39.6%) | 34 (54.8%) | 10 (52.4%) | ||||
| Male | 777 (60.4%) | 29 (45.2%) | 10 (47.6%) | ||||
| Location | <0.001 | <0.001 | <0.001 | 0.077 | |||
| Proximal colon | 290 (22.5%) | 35 (56.4%) | 17 (80.9%) | ||||
| Distal colon | 526 (40.9%) | 14 (22.6%) | 4 (19.0%) | ||||
| Rectum | 471 (36.6%) | 13 (21.0%) | 0 (0.0%) | ||||
| Gross pattern | 0.517 | 0.800 | 0.760 | 0.960 | |||
| Fungating | 851 (66.1%) | 38 (61.3%) | 12 (57.1%) | ||||
| Ulcerative | 436 (33.9%) | 24 (38.7%) | 9 (42.9%) | ||||
| T category | 0.001 | 0.004 | 0.343 | 0.895 | |||
| T1 | 56 (4.4%) | 0 (0.0%) | 0 (0.0%) | ||||
| T2 | 196 (15.2%) | 2 (3.2%) | 0 (0.0%) | ||||
| T3 | 913 (71.0%) | 47 (75.8%) | 19 (90.5%) | ||||
| T4 | 121 (9.4%) | 13 (21.0%) | 2 (9.5%) | ||||
| N category | <0.001 | <0.001 | 0.884 | 0.200 | |||
| N0 | 665 (51.7%) | 17 (27.4%) | 9 (42.9%) | ||||
| N1 | 354 (27.5%) | 17 (27.4%) | 8 (38.1%) | ||||
| N2 | 268 (20.8%) | 28 (45.2%) | 4 (19.0%) | ||||
| M category | 0.053 | 0.430 | 0.630 | 0.320 | |||
| M0 | 1075 (83.5%) | 46 (74.2%) | 20 (95.2%) | ||||
| M1 | 212 (16.5%) | 16 (25.8%) | 1 (4.8%) | ||||
| Stage | 0.001 | 0.001 | 0.904 | 0.300 | |||
| I | 205 (15.9%) | 0 (0.0%) | 0 (0.0%) | ||||
| II | 421 (32.7%) | 17 (27.4%) | 9 (42.9%) | ||||
| III | 450 (35.0%) | 29 (46.8%) | 11 (52.4%) | ||||
| IV | 211 (16.4%) | 16 (25.8%) | 1 (4.8%) | ||||
| KRAS | 0.103 | 0.799 | 0.103 | 0.088 | |||
| Wild type | 892 (69.3%) | 40 (64.5%) | 20 (95.2%) | ||||
| Mutated | 395 (30.7%) | 22 (35.5%) | 1 (4.8%) | ||||
| BRAF | <0.001 | 0.290 | 0.110 | 0.600 | |||
| Wild type | 1245 (96.7%) | 53 (85.5%) | 15 (71.4%) | ||||
| Mutated | 42 (3.3%) | 9 (14.5%) | 6 (28.6%) | ||||
| MSI | <0.001 | 0.008 | <0.001 | 0.001 | |||
| MSS | 1120 (87.0%) | 41 (66.1%) | 4 (19.1%) | ||||
| MSI-low | 96 (7.5%) | 4 (6.5%) | 0 (0.0%) | ||||
| MSI-high | 71 (5.5%) | 17 (27.4%) | 17 (80.9%) | ||||
| MLH1 | <0.001 | 0.073 | <0.001 | <0.001 | |||
| Unmethylated | 1270 (98.7%) | 51 (80.9%) | 3 (15.0%) | ||||
| Methylated | 17 (1.3%) | 11 (17.7%) | 18 (85.7%) | ||||
| CK7 expression | <0.001 | 0.062 | <0.001 | 0.020 | |||
| Not expressed | 1197 (93.0%) | 51 (82.3%) | 14 (66.7%) | ||||
| Expressed | 90 (7.0%) | 11 (17.7%) | 7 (33.3%) | ||||
| CK20 expression | <0.001 | 0.210 | 0.220 | 0.810 | |||
| Retained | 1091 (84.7%) | 42 (67.7%) | 6 (28.6%) | ||||
| Decreased | 196 (15.3%) | 20 (32.3%) | 15 (71.4%) | ||||
| CDX2 expression | <0.001 | <0.001 | <0.001 | 0.590 | |||
| Retained | 1172 (91.3%) | 30 (48.4%) | 7 (33.3%) | ||||
| Decreased | 111 (8.7%) | 32 (51.6%) | 14 (66.7%) |
Abbreviations: MSI=microsatellite instability; MSS=microsatellite stable.